Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Remus PharmaceuticalsNSE:REMUS -0.42%55 Debt-to-EBITDA is 0.40 as of Mar. 2026, which is 11% above its 10-year median of 0.36. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 92 Medical Distribution companies, Remus Pharmaceuticals ranks better than 83.7% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Remus Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
NSE:REMUS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.04 Med: 0.36 Max: 0.45
Current: 0.43
During the past 7 years, the highest Debt-to-EBITDA Ratio of Remus Pharmaceuticals was 0.45. The lowest was 0.04. And the median was 0.36.
NSE:REMUS's Debt-to-EBITDA is ranked better than 83.7% of 92
companies
in the Medical Distribution industry
Industry Median: 2.43
vs NSE:REMUS: 0.43
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Remus Pharmaceuticals Debt-to-EBITDA Related Terms
Remus Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, COR, CAH: Debt-to-EBITDA Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Debt-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Remus Pharmaceuticals (NSE:REMUS) has a Debt-to-EBITDA of 0.40 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Remus Pharmaceuticals. This is 11% above median its historical median of 0.36. Over the past decade, Remus Pharmaceuticals' Debt-to-EBITDA has ranged from 0.04 to 0.45. According to the industry distribution chart, Remus Pharmaceuticals ranks #15 out of 92 companies in the Medical Distribution industry, placing it in the top 16.3%.
Is Remus Pharmaceuticals' Debt-to-EBITDA too high?
Remus Pharmaceuticals' current Debt-to-EBITDA of 0.40 is 11% above median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.45. The Medical Distribution industry median Debt-to-EBITDA is 2.43. Remus Pharmaceuticals' value of 0.40 is 83.5% below this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #15 out of 92 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Debt-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #15 out of 92 companies for Debt-to-EBITDA. This places Remus Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.43. Remus Pharmaceuticals' value of 0.40 is 83.5% below this benchmark. Historically, Remus Pharmaceuticals' own Debt-to-EBITDA has ranged from 0.04 to 0.45 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 2.43, Remus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Distribution company?
The median Debt-to-EBITDA among Medical Distribution companies is 2.43, based on 92 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Debt-to-EBITDA of 0.40 is 83.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Remus Pharmaceuticals. For the Medical Distribution industry, the median Debt-to-EBITDA is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Debt-to-EBITDA is 0.40, which is 11% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹845.15 — trading 59.2% below its estimated fair value. The current Debt-to-EBITDA is 0.40, which is 11% above median its 10-year median of 0.36 and 83.5% below the Medical Distribution industry median of 2.43. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Debt-to-EBITDA is 0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹845.15 is trading 59.2% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Debt-to-EBITDA: 0.40 (11% above median its 10-year median of 0.36)
GF Value™: ₹2,071.36 vs. price of ₹845.15 (59.2% below fair value)
Industry Position: 83.5% below the Medical Distribution median (#15 of 92)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
